Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Cash-to-Debt : 22.54 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Sonnet BioTherapeutics Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sonnet BioTherapeutics Holdings's cash to debt ratio for the quarter that ended in Mar. 2024 was 22.54.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sonnet BioTherapeutics Holdings could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Sonnet BioTherapeutics Holdings's Cash-to-Debt or its related term are showing as below:

SONN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 19.98 Max: 219.22
Current: 22.54

During the past 5 years, Sonnet BioTherapeutics Holdings's highest Cash to Debt Ratio was 219.22. The lowest was 0.02. And the median was 19.98.

SONN's Cash-to-Debt is ranked better than
64.75% of 1478 companies
in the Biotechnology industry
Industry Median: 7.005 vs SONN: 22.54

Sonnet BioTherapeutics Holdings Cash-to-Debt Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Sonnet BioTherapeutics Holdings Cash-to-Debt Chart

Sonnet BioTherapeutics Holdings Annual Data

Trend

Sep19

Sep20

Sep21

Sep22

Sep23

Cash-to-Debt

0.17

20.82

219.22

11.93

11.15

Sonnet BioTherapeutics Holdings Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial													47.86	31.91	11.15	16.16	22.54

Competitive Comparison of Sonnet BioTherapeutics Holdings's Cash-to-Debt

For the Biotechnology subindustry, Sonnet BioTherapeutics Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sonnet BioTherapeutics Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sonnet BioTherapeutics Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Sonnet BioTherapeutics Holdings's Cash-to-Debt falls into.

Sonnet BioTherapeutics Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Sonnet BioTherapeutics Holdings's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.274	/	(0.073	+	0.131)
	=	11.15

Sonnet BioTherapeutics Holdings's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.786	/	(0.078	+	0.09)
	=	22.54

Sonnet BioTherapeutics Holdings (NAS:SONN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Sonnet BioTherapeutics Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540

Website

https://www.sonnetbio.com

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Executives

John Markey	10 percent owner	10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087
Susan Dexter	officer: Chief Technical Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Albert D. Dyrness	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Nailesh Bhatt	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Pankaj Mohan	director, officer: Chairman, President and CEO	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Lori Mcneill	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540
Richard T Kenney	officer: Chief Medical Officer	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Donald J. Griffith	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Terence Anthony Rugg	officer: Chief Medical Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
John K. Cini	officer: Chief Scientific Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Raghu Rao	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Cross John Harry Iii	officer: Chief Financial Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Oz Rey Llc	10 percent owner	918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701
Mv Amanth Llc	10 percent owner	515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516
Robert Sumner Hersch	10 percent owner	515 CONGRESS AVE, STE 1400, AUSTIN TX 78701